Real-World Evidence in Oncology: Opportunities and Limitations

被引：111

作者：

Di Maio, Massimo ^{[1
,2
]}

Perrone, Francesco ^{[3
]}

Conte, Pierfranco ^{[4
,5
]}

机构：

[1] Univ Turin, Dept Oncol, Turin, Italy

[2] Ordine Mauriziano Hosp, Turin, Italy

[3] IRCCS Fdn Pascale, Natl Canc Inst, Clin Trial Unit, Naples, Italy

[4] Univ Padua, Dept Surg Oncol & Gastroenterol, Via Gattamelata 64, I-35128 Padua, Italy

[5] IRCCS, Ist Oncol Veneto, Oncol Med 2, Via Gattamelata 64, I-35128 Padua, Italy

来源：

ONCOLOGIST | 2020年 / 25卷 / 05期

关键词：

Real-world evidence; Clinical trials; Cancer treatments; TRIALS; TRASTUZUMAB; SORAFENIB; DOCETAXEL;

D O I：

10.1634/theoncologist.2019-0647

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：E746 / E752

页数：7

共 29 条

[1]

Bang YJ, 2010, LANCET, V376, P1302

[2] Addressing the affordability of cancer drugs: using deliberative public engagement to inform health policy [J].

Bentley, Colene ;

Peacock, Stuart ;

Abelson, Julia ;

Burgess, Michael M. ;

Demers-Payette, Olivier ;

Longstaff, Holly ;

Tripp, Laura ;

Lavis, John N. ;

Wilson, Michael G. .

HEALTH RESEARCH POLICY AND SYSTEMS, 2019, 17 (1)

[3] Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer [J].

Blomstrand, Hakon ;

Scheibling, Ursula ;

Bratthall, Charlotte ;

Green, Henrik ;

Elander, Nils O. .

BMC CANCER, 2019, 19 (1)

[4] Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study [J].

Boegemann, Martin ;

Khaksar, Sara ;

Bera, Guillaume ;

Birtle, Alison ;

Dopchie, Catherine ;

Dourthe, Louis-Marie ;

Everaert, Els ;

Hatzinger, Martin ;

Hercher, Dirko ;

Hilgers, Werner ;

Matus, Geoffrey ;

Garcia Alvarez, Laura ;

Antoni, Laurent ;

Lukac, Martin ;

Pissart, Genevieve ;

Robinson, Paul ;

Elliott, Tony .

BMC CANCER, 2019, 19 (1)

[5] Real-world data: towards achieving the achievable in cancer care [J].

Booth, Christopher M. ;

Karim, Safiya ;

Mackillop, William J. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (05) :312-325

[6] Systematic Review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy [J].

Bossi, Paolo ;

Botta, Laura ;

Bironzo, Paolo ;

Sonetto, Cristina ;

Musettini, Gianna ;

Sbrana, Andrea ;

Di Giannantonio, Valerio ;

Locati, Laura D. ;

Di Maio, Massimo ;

Antonuzzo, Andrea .

FUTURE ONCOLOGY, 2019, 15 (21) :2543-2553

[7] Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].

Cheng, Ann-Lii ;

Kang, Yoon-Koo ;

Chen, Zhendong ;

Tsao, Chao-Jung ;

Qin, Shukui ;

Kim, Jun Suk ;

Luo, Rongcheng ;

Feng, Jifeng ;

Ye, Shenglong ;

Yang, Tsai-Sheng ;

Xu, Jianming ;

Sun, Yan ;

Liang, Houjie ;

Liu, Jiwei ;

Wang, Jiejun ;

Tak, Won Young ;

Pan, Hongming ;

Burock, Karin ;

Zou, Jessie ;

Voliotis, Dimitris ;

Guan, Zhongzhen .

LANCET ONCOLOGY, 2009, 10 (01) :25-34

[8] Real-world data for efficient health technology assessment [J].

Hall, Peter S. .

EUROPEAN JOURNAL OF CANCER, 2017, 79 :235-237

[9] Can it work? Does it work? Is it worth it? The testing of healthcare interventions is evolving [J].

Haynes, B .

BRITISH MEDICAL JOURNAL, 1999, 319 (7211) :652-653

[10] Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations [J].

Hyman, David M. ;

Puzanov, Igor ;

Subbiah, Vivek ;

Faris, Jason E. ;

Chau, Ian ;

Blay, Jean-Yves ;

Wolf, Juergen ;

Raje, Noopur S. ;

Diamond, Eli L. ;

Hollebecque, Antoine ;

Gervais, Radj ;

Elena Elez-Fernandez, Maria ;

Italiano, Antoine ;

Hofheinz, Ralf-Dieter ;

Hidalgo, Manuel ;

Chan, Emily ;

Schuler, Martin ;

Lasserre, Susan Frances ;

Makrutzki, Martina ;

Sirzen, Florin ;

Veronese, Maria Luisa ;

Tabernero, Josep ;

Baselga, Jose .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (08) :726-736

← 1 2 3 →